Bårnes Camilla Boslev, Ulrik Charlotte Suppli
Department of Pulmonary Medicine, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark.
Respir Care. 2015 Mar;60(3):455-68. doi: 10.4187/respcare.03200. Epub 2014 Aug 12.
Inhaled corticosteroids (ICS) are the cornerstone of maintenance asthma therapy. However, in spite of this, adherence to ICS remains low. The aim of this systematic literature review was to provide an overview of the current knowledge of adherence to ICS, effects of poor adherence, and means to improve adherence. A total of 19 studies met the inclusion criteria: 9 focusing on the level of adherence, 6 focusing on effects of poor adherence, and 7 focusing on interventions to improve adherence. Three of the studies focused on more than one of these end points. The mean level of adherence to ICS was found to be between 22 and 63%, with improvement up to and after an exacerbation. Poor adherence was associated with youth, being African-American, having mild asthma, < 12 y of formal education, and poor communication with the health-care provider, whereas improved adherence was associated with being prescribed fixed-combination therapy (ICS and long-acting β2 agonists). Good adherence was associated with higher FEV1, a lower percentage of eosinophils in sputum, reduction in hospitalizations, less use of oral corticosteroids, and lower mortality rate. Overall, 24% of exacerbations and 60% of asthma-related hospitalizations could be attributed to poor adherence. Most studies have reported an increase in adherence following focused interventions, followed by an improvement in quality of life, symptoms, FEV1, and oral corticosteroid use. However, 2 studies found no difference in health-care utilization, one observed no effect on symptoms, and one observed more symptoms in subjects in the intervention group compared with the control group. Good adherence to ICS in asthma improves outcome but remains low. Interventions to improve adherence show varying results, with most studies reporting an increase in adherence but unfortunately not necessarily an improvement in outcome. Even following successful interventions, adherence remains low. Further research is needed to explore barriers to adherence and interventions for improvement.
吸入性糖皮质激素(ICS)是哮喘维持治疗的基石。然而,尽管如此,ICS的依从性仍然很低。本系统文献综述的目的是概述当前关于ICS依从性、依从性差的影响以及提高依从性方法的知识。共有19项研究符合纳入标准:9项关注依从性水平,6项关注依从性差的影响,7项关注提高依从性的干预措施。其中3项研究关注了不止一个这些终点。发现ICS的平均依从性水平在22%至63%之间,在病情加重期间及之后有所改善。依从性差与年轻、非裔美国人、患有轻度哮喘、正规教育年限<12年以及与医疗服务提供者沟通不良有关,而依从性提高与接受固定复方治疗(ICS和长效β2激动剂)有关。良好的依从性与较高的第一秒用力呼气容积(FEV1)、痰液中嗜酸性粒细胞百分比降低、住院次数减少、口服糖皮质激素使用减少以及死亡率降低有关。总体而言,24%的病情加重和60%的哮喘相关住院可归因于依从性差。大多数研究报告称,针对性干预后依从性有所提高,随后生活质量、症状、FEV1和口服糖皮质激素使用情况有所改善。然而,有2项研究发现医疗服务利用方面没有差异,1项研究观察到对症状没有影响,还有1项研究观察到干预组受试者的症状比对照组更多。哮喘患者对ICS的良好依从性可改善预后,但依从性仍然很低。提高依从性的干预措施结果各异,大多数研究报告依从性有所提高,但遗憾的是不一定能改善预后。即使在成功干预之后,依从性仍然很低。需要进一步研究以探索依从性的障碍和改善依从性的干预措施。